We believe our approach could result in better targeted cancer therapies. Examples of these mechanisms are shown in the figure below. & & MYB or MYBL1 gene fusions lead to overexpression of the MYB/ MYBL1 protein. We have recently completed the dose escalation portion of the trial. PRT543 Inhibits the Growth of HRD+ Breast Cancer Cell Lines. & & P < 0.05, ** P < 0.01 vs. vehicle by Mann-Whitney U test. & & Data represent mean ± SEM with 8 mice/group. dose level demonstrated an approximately 66% reduction in TSS. Total expected enrollment is anticipated to be approximately 160 patients. There were no patients that discontinued study 21 & & therapy due to an adverse event. dose level and one out of six Group B patients at the 40 mg t.i.w. We believe our optimal dose will be between 22.5 mg and 50 mg. PRT543 treatment was associated with reductions in these markers. A second MF patient at the 40 mg t.i.w. In this model, the U87 glioblastoma cells were implanted directly in the brain. No dose limiting toxicities have been observed as of September 1, 2020. Mean data are shown in Table 5. Diffuse large B-cell lymphoma, or DLBCL, is the most common of these aggressive subtypes. MM is primarily a disease of the elderly and has a five-year survival rate of 54%. & The treatment of MM depends on the aggressiveness of disease and patient fitness. MM therapies generated approximately $19.4 billion in world-wide sales in 2019. & 40 & & & PRT811 & Our PRT811 patent portfolio is wholly owned by us. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. The applicant under an approved NDA is also subject to annual program fees. Coverage policies and third-party reimbursement rates may change at any time. 8226; We are very early in our development efforts. As of December 31, 2020, we had an accumulated deficit of $107.4 million. We will require substantial additional funding to pursue our business objectives. We have not obtained FDA approval for any product. The approval procedure varies among countries and can involve additional testing. State and local laws require the registration of pharmaceutical sales representatives. We generally contract with third parties for the disposal of these materials and wastes. We have not yet scaled up the manufacturing process for any of our product candidates. We face significant competition in seeking appropriate collaborators. Insurance coverage is increasingly expensive. For example, the CARES Act modified certain provisions of the Tax Cuts and Jobs Act. We do not yet have issued patents on all of our product candidates. & Intellectual property rights do not necessarily address all potential threats. & The market value of our common stock may decrease from the purchase price. We expect our operating results to be subject to quarterly fluctuations. We may be the target of this type of litigation in the future.
